The aim of the study is to collect, under daily practice conditions, clinical data on the
safety profile and the efficacy of a new formulation of alfuzosin administered once daily in
patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia
(BPH).